This is a working overview of circadian rhythm, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-20 and is reviewed periodically as new material appears.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
== Treatment == Once NAION happens, it was thought that there was no accepted treatment to reverse the damage. However, a recent uncontrolled retrospective large study has shown that if patients are treated with large doses of corticosteroid therapy during the early stages of NAION, in eyes with initial visual acuity of 20/70 or worse, seen within 2 weeks of onset, there was visual acuity improvement in 70% in the treated group compared to 41% in the untreated group (odds ratio of improvement: 3.39; 95% CI:1.62, 7.11; p < 0.001). That study and a natural history study on NAION (Ophthalmology 2008;115: 298–305.) showed that visual acuity can improve up to 6 months and not after that. To minimize the risk of further visual loss in the fellow eye or the same eye, it is essential to reduce the risk factors. Common sense dictates trying to control the cardiovascular risk factors for many reasons, including protection from this happening to the second eye. Sudden vision loss should lead to an ophthalmological consultation. If NAION is suspected, then ideally a neuro-ophthalmologist's consultation should be obtained. A recent Cochrane Review sought to determine the extent of safety and efficacy of optic nerve decompression surgery for NAION, compared to other treatments, or no treatment. The one study included in the review found no improvements in visual acuity among patients who underwent surgery for NAION, and adverse events (pain, double vision) experienced by participants who underwent surgery.
=== Monitor/recorder === The flow cells are connected to a display and/or recorder. On older systems this was a simple chart recorder, on modern systems a computer with hardware interface and display is used. This permits the experimenter to identify when peaks in protein concentration occur, indicating that specific components of the mixture are being eluted.
While there is limited literature on radiation injury to animals, there is no evidence of other types of radiation injury. Diagnostic radiation has been shown to cause local burns in animals, typically resulting from prolonged exposure of body parts or sparks from old x-ray tubes. It is important to note that the frequency of injury to veterinary staff and veterinarians is significantly lower than that in human medicine, highlighting the safety of diagnostic radiation in veterinary practice. In veterinary medicine, fewer images are taken compared to human medicine, particularly fewer CT scans. However, due to the manual restraint of animals to avoid anesthesia, at least one person is present in the control area, resulting in significantly higher radiation exposure than that of human medical staff. It is important to note that since the 1970s, dosimeters have been used to measure the radiation exposure of veterinary personnel, ensuring their safety. Feline hyperthyroidism (overactive thyroid) is a common disease in older cats. Radioiodine therapy is considered by many authors to be the treatment of choice. Following the administration of radioactive iodine, cats are kept in an isolation pen. The cat's radioactivity is measured to determine the time of discharge, which is typically 14 days after the start of therapy. The therapy requires significant radiation protection measures and is currently only offered at two veterinary facilities in Germany (as of 2010).
Sources: en.wikipedia.org
Humphreys' study has been criticized by sociologists and other social and behavioral scientists on ethical grounds in that he observed sexual acts by masquerading as a voyeur, "did not get his subjects’ consent, tracked down names and addresses through license plate numbers, and interviewed the men in their homes in disguise and under false pretenses." According to Jack Nusan Porter, a sociologist who knew Humphreys and studied under Howard S. Becker at Northwestern University from 1967 to 1971, "Humphreys was enormously influential on graduate students and younger scholars in the field of deviance, ethnography, and what we called 'participant observation'. True, today one could not do such research because there was no 'informed consent' but then again, in many cases, when doing research on deviant behavior, one will never get 'informed consent' so we miss out on a lot of important findings. He was a true pioneer and a hero to all of us in these fields." Humphreys' research materials, including detailed diagrams and maps of tearoom activity he observed, are housed in the collections at ONE National Gay & Lesbian Archives. By 2004, Tearoom Trade had sold more than 300,000 copies. Steven P. Schacht notes that this fact "makes it one of the best selling books ever written by a sociologist." The book was also published by Gerald Duckworth & Co. in British English, and in German by Ferdinand Enke Vertag. Both of these versions were published in 1974.
== See also == Aneutronic fusion Cold fusion Fusion power Neutrino astronomy Nuclear fusion Proton–proton chain, as found in stars like the Sun Stellar nucleosynthesis, the whole topic Triple-alpha process, how 12C is produced from lighter nuclei
Emil Siebel, the son of the founder of the Zymotechnic Institute, broke away from his father's company to establish his own called the "Bureau of Biotechnology," which specifically offered expertise in fermented nonalcoholic drinks. The belief that the needs of an industrial society could be met by fermenting agricultural waste was an important ingredient of the "chemurgic movement." Fermentation-based processes generated products of ever-growing utility. In the 1940s, penicillin was the most dramatic. While it was discovered in England, it was produced industrially in the U.S. using a deep fermentation process originally developed in Peoria, Illinois. The enormous profits and the public expectations penicillin engendered caused a radical shift in the standing of the pharmaceutical industry. Doctors used the phrase "miracle drug", and the historian of its wartime use, David Adams, has suggested that to the public penicillin represented the perfect health that went together with the car and the dream house of wartime American advertising. Beginning in the 1950s, fermentation technology also became advanced enough to produce steroids on industrially significant scales. Of particular importance was the improved semisynthesis of cortisone which simplified the old 31 step synthesis to 11 steps. This advance was estimated to reduce the cost of the drug by 70%, making the medicine inexpensive and available. Today biotechnology still plays a central role in the production of these compounds and likely will for years to come.
linking to primary rather than secondary sources and prioritizing stable sites avoiding links that point to resources on researchers' personal pages using clean URLs or otherwise employing URL normalization or URL canonicalization using permalinks and persistent identifiers such as ARKs, DOIs, Handle System references, PURLs, or content addressing avoiding linking to documents other than web pages avoiding deep linking linking to web archives such as the Internet Archive, WebCite, archive.today, Perma.cc, Amber, or Arweave Strategies pertaining to the protection of existing links include:
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.